Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.

Abstract

PURPOSE Most guidelines for hormone receptor (HR)-positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable morbidity and cost. There has been recent incorporation of gene expression analysis in aiding decision making. We evaluated the cost-effectiveness of recurrence score… (More)
DOI: 10.1634/theoncologist.2009-0275

Topics

Cite this paper

@article{Tsoi2010CosteffectivenessAO, title={Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.}, author={Daphne T. Tsoi and Miho Inoue and Catherine Kelly and Sunil P. Verma and Kathleen I. Pritchard}, journal={The oncologist}, year={2010}, volume={15 5}, pages={457-65} }